FasTCAR T

FasTCAR T is a next-generation autologous CAR-T cell therapy platform developed by Gracell Biotechnologies, designed to accelerate the manufacturing process for patient-specific CAR-T cell therapies used in cancer and autoimmune diseases. The platform enables concurrent activation and transduction of resting T cells in a single fully-closed system step using proprietary XLenti vectors, bypassing the need for extended ex vivo expansion and reducing the manufacturing time from the traditional 1–6 weeks to just overnight[1]. FasTCAR T-cells are reported to exhibit enhanced stemness and proliferation, appearing "younger" and "less exhausted" than conventional CAR-T cells, potentially leading to improved persistence and anti-tumor activity, with possible lower dosage requirements[1]. The primary indication is for the treatment of cancers, with broader potential in autoimmune diseases[1]. This technology aims to address key industry challenges such as contamination risk, operational consistency, and extended patient wait times for cell therapy[1].

Brand names

FasTCAR

Other names

Fast-CAR-TFastCARrapid autologous CAR-T cell manufacturing platform